LATEST

Guarded approval for new USPSTF PSA gradeThe new draft recommendation on PSA screening from the U.S. Preventive Services Task Force (USPSTF), which improves the previous D rating for all men to a C rating for those ages 55 to 69 years, has been met with guarded approval by three of the key national organizations representing urologists.
MACRA: A practical perspective for urologistsThis article provides a practical explanation of MACRA and the Quality Payment Program and what they mean for practicing urologists.
New Products: Nasal spray to treat nocturia receives FDA approvalOther products discussed include catheter sets to make the ordering process easier, a micro-US/MRI fusion application for prostate imaging, an international prostate registry for HIFU and more.
Updated prostate Bx paper outlines preventive strategiesA recently updated white paper from the AUA and the Society of Urologic Nurses and Associates includes new data on the prevalence of prostate biopsy-related complications and outlines the current preventive strategies. In this installment of "Journal Article of the Month," Badar M. Mian, MD, gives an overview and analysis of the updated paper.
What’s new in prostate Ca tests: Markers, imagingIn this article, urologists Scott E. Eggener, MD, and Stacy Loeb, MD, MSc, discuss the current applications for prostate cancer biomarkers and MRI, their impact on clinical practice, and future developments.
Immunotherapy for GU Ca: A primer for urologistsThis article discusses the current status and potential future developments in immunotherapy for genitourinary malignancies with insights from urologic oncology specialists Hyung L. Kim, MD, and Daniel P. Petrylak, MD.
Biomarkers for bladder cancer: Current and futureThe role of protein- and cell-based urinary biomarkers for bladder cancer detection and surveillance is controversial, and in 2017 these assays have yet to come into widespread use among urologists. Their uptake is expected to increase, however, considering that the AUA/Society of Urologic Oncology “Guideline on Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer” that was released in 2016 identifies situations for using urinary biomarkers, according to Badrinath R. Konety, MD.
Guidelines update: Bladder, kidney, prostate cancerThis article highlights the key points of two urologic cancer guidelines (which provide evidence-based guidance) and two consensus statements (which provide consensus recommendations by a multidisciplinary panel of experts) that have been published in the past year.
How to estimate life expectancy in men with localized prostate CaWhile no resource is perfect, it is worthwhile to familiarize yourself with some contemporary methodology and predictive tools to help determine life expectancy in localized prostate cancer patients.
Small molecule RNA inhibitor shows promise in PCaTargeted treatment with a small molecule RNA inhibitor demonstrates promising activity for promoting apoptosis of prostate cancer cells in culture, report investigators from Scripps Florida.

Poll

View Results